To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal TreatmentEarly Phase 1Post-EndodontiNCT07064083
The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain
A Early Phase 1 study testing intracanal nano-ketrolac and ketrolac gel in people with To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal Treatment, run by Al-Azhar University at 1 site in Egypt.
Trial summary
After obtaining informed consent, the procedure begins with the administration of local anesthesia to ensure patient comfort. A standard approach involves using 2% lidocaine with 1:100,000 epinephrine, delivered either via infiltration for maxillary teeth or mental nerve block for mandibular posterior teeth. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal Treatment
- What is being tested?
- intracanal nano-ketrolac and ketrolac gel
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2025to 26 Feb 2026
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients aged 18-50 years.
- Patients who are diagnosed with necrotic pulp and chronic apical periodontitis in a single-rooted tooth.
- Patients who provide written informed consent.
- Patients with no systemic diseases affecting pain perception or wound healing.
Who cannot join
- Patients with irreversible pulpitis or acute periapical abscess
- Patients with a history of NSAID or opioid use within 24 hours before treatment.
- Pregnant or lactating women.
- Patients who require more than two-visits root canal treatment due to anatomical or pathological factors.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Collage of Oral and Dental Surgery, Misr University for Science and Technology
Giza
About this study
Official title: The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain: A Randomized Controlled Clinical Trial
After obtaining informed consent, the procedure begins with the administration of local anesthesia to ensure patient comfort. A standard approach involves using 2% lidocaine with 1:100,000 epinephrine, delivered either via infiltration for maxillary teeth or mental nerve block for mandibular posterior teeth. Adequate anesthesia is confirmed using a cold test or gentle probing. Once profound anesthesia is achieved, rubber dam isolation is placed to maintain an aseptic field and prevent contamination. The operative field is then disinfected with 5% sodium hypochlorite before proceeding to the access cavity preparation.
The access cavity is prepared using a high-speed diamond bur under continuous water coolant. The shape of the access cavity is determined by the tooth's anatomy, ensuring straight-line access to the canal system. Once the pulp chamber is opened, the roof is carefully removed using a round bur or ultrasonic tips, exposing the canal orifices. The chamber is then thoroughly irrigated with 2.5% sodium hypochlorite to remove any residual pulp tissue and debris. A DG16 endodontic explorer is used to locate the canal orifices, after which initial canal exploration is performed using a #10 or #15 K-file to check for patency.
Read more
Working length determination follows, utilizing an electronic apex locator (EAL) to establish the length of the canal. A confirmation periapical radiograph is taken to verify the readings. To maintain apical patience, a #10 K-file is used in a gentle watch-winding motion until it reaches the apical constriction. The glide path is then established to facilitate subsequent instrumentation. This is achieved by sequentially using hand files (#10, 15, and 20 K-files) with a balanced force technique until a #20 file moves freely to the working length. Throughout this process, frequent irrigation with 2.5% sodium hypochlorite is performed to flush out debris and maintain canal cleanliness.
Once the glide path is established, shaping of the canal begins based on the size of the initial binding file, which is the first file to engage the canal walls at the working length. If the initial binding file is #10 or #15, the apical preparation is typically completed up to a size #35, while an initial binding file of #20 may require enlargement to #40 or #50. Canal shaping is performed using a crown-down technique with rotary nickel-titanium (NiTi) instruments.
Throughout the shaping process, continuous irrigation with sodium hypochlorite to dissolve organic debris and disinfect the canal is performed with total volume of 10ml/canal. After the final shaping, the canal is dried with sterile paper points, leaving it ready for medication placement. For the subjects of GI and GII, nano-ketorolac gel and ketorolac gel respectively (Around 2mm3), placed as medicament inside the root canal while those of GIII a placebo gel is placed. Both will be retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
Randomization and Blinding:
Randomization will be performed using a computer-generated sequence. The patients and outcome assessors will be blinded to the group allocation. Nano-ketorolac production
This study, a formulation containing Ketorolac Tromethamine (KT) at a concentration of 10 mg/mL were developed using Compritol 888 as distinct oleaginous phases. Span 60 was incorporated as a surfactant at a concentration of 1.5%, while the drug-to-oleaginous phase ratio was maintained at 1:2. The Solid Lipid Nanoparticles (SLNs) were formulated using high-shear homogenization to ensure optimal particle size and stability. The nano-Ketorolac will be manufactured in the college of phramaceutical sciences and drug manufacturing, Misr University for Science and Technology, , Egypt.
Statistical Analysis Data will be analyzed using SPSS software. Data will be tested for its normal distribution; accordingly, the appropriate test will be conducted. Statistical significance will be set at p < 0.05.
Ethical Considerations
- The study will be conducted in accordance with the Declaration of Helsinki.
- Ethical approval will be obtained from the Institutional Ethical Committee of Misr University for Science and Technology.
- Informed consent will be obtained from all participants before their inclusion.
- Patients will be informed of their right to withdraw at any time without consequences.
- Data confidentiality will be maintained throughout the study.
Pain management in endodontics has been extensively studied, with a focus on pharmacological interventions, anesthetic techniques, and intracanal medicaments to improve post-operative outcomes. Several studies have explored the effectiveness of NSAIDs, corticosteroids, and advanced anesthetic techniques in controlling pain, but challenges persist, particularly in cases involving necrotic pulp and apical periodontitis.
Read the detailed description
Study Design: This study will be a randomized, double-blinded, placebo-controlled clinical trial.
Participants and Setting: The study will be conducted at the clinics of Collage of Oral and dental surgery, Misr University for Science and Technology. Patients diagnosed with necrotic pulp and apical periodontitis requiring root canal treatment will be recruited.
- Being tested
- intracanal nano-ketrolac, ketrolac gel, A placebo gel
- Keywords
- postendodontic pain, nano-ketrolac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intracanal nano-ketrolacDrug
For the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
ketrolac gelDrug
For the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
A placebo gelDrug
a placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
| Study group | Role | What they receive |
|---|---|---|
| GI | Experimental | The nano-ketrolac gel will be introduced intracanal after cleaning and shaping is performed. Receives: Drug: intracanal nano-ketrolac |
| GII | Experimental | ketrolac gel will be introduced intracanal after cleaning and shaping is performed. Receives: Drug: ketrolac gel |
| GIII | Placebo comparator | A placebo gel will be introduced intracanal after cleaning and shaping is performed. Receives: Drug: A placebo gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
post-endodontic pain
Pain intensity will be assessed using the Visual Analog Scale (VAS) on a 10-point scale (0 = no pain, 10 = worst pain imaginable
Measured: • Pre-treatment (baseline) • 6 hours post-treatment • 12 hours post-treatment • 24 hours post-treatment • 48 hours post-treatment • 7 days post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start1 Aug 2025
- Primary completion26 Feb 2026
- Study completion26 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal TreatmentStudies of the same condition, open and under way.
- More trials run by Al-Azhar UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized, double-blinded, placebo-controlled clinical trial
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Al-Azhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sabah Morad Sobhy, Al-Azhar University
- Investigators
- Eman Maged Fouad, PHD, Principal investigator, Lecturer of Endodontics, Collage of Oral and Dental Surgery, Misr University for Science and Technology, Giza, Egypt.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07064083
- Sponsor's protocol ID
- 2025/0036
- Acronym
- Post-Endodonti
- Status last verified
- Aug 2026
- First submitted
- 3 Jul 2025
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kumar G, Jena S, Manila N, Fareed M, Karobari MI. Incidence of postoperative pain after single-visit and multiple-visit root canal therapy: a systematic review. BMC Oral Health. 2025 Jan 8;25(1):47. doi: 10.1186/s12903-024-05412-1.
PubMed 39780175
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain: A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07064083
- Acronym / sponsor ID
- Post-Endodonti / 2025/0036
- Keywords
- postendodontic pain, nano-ketrolac
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Al-Azhar UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 26 Feb 2026 (actual)
- Study completion
- 26 Feb 2026 (actual)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After obtaining informed consent, the procedure begins with the administration of local anesthesia to ensure patient comfort. A standard approach involves using 2% lidocaine with 1:100,000 epinephrine, delivered either via infiltration for maxillary teeth or mental nerve block for mandibular posterior teeth. Adequate anesthesia is confirmed using a cold test or gentle probing. Once profound anesthesia is achieved, rubber dam isolation is placed to maintain an aseptic field and prevent contamination. The operative field is then disinfected with 5% sodium hypochlorite before proceeding to the access cavity preparation.
The access cavity is prepared using a high-speed diamond bur under continuous water coolant. The shape of the access cavity is determined by the tooth's anatomy, ensuring straight-line access to the canal system. Once the pulp chamber is opened, the roof is carefully removed using a round bur or ultrasonic tips, exposing the canal orifices. The chamber is then thoroughly irrigated with 2.5% sodium hypochlorite to remove any residual pulp tissue and debris. A DG16 endodontic explorer is used to locate the canal orifices, after which initial canal exploration is performed using a #10 or #15 K-file to check for patency.
Working length determination follows, utilizing an electronic apex locator (EAL) to establish the length of the canal. A confirmation periapical radiograph is taken to verify the readings. To maintain apical patience, a #10 K-file is used in a gentle watch-winding motion until it reaches the apical constriction. The glide path is then established to facilitate subsequent instrumentation. This is achieved by sequentially using hand files (#10, 15, and 20 K-files) with a balanced force technique until a #20 file moves freely to the working length. Throughout this process, frequent irrigation with 2.5% sodium hypochlorite is performed to flush out debris and maintain canal cleanliness.
Once the glide path is established, shaping of the canal begins based on the size of the initial binding file, which is the first file to engage the canal walls at the working length. If the initial binding file is #10 or #15, the apical preparation is typically completed up to a size #35, while an initial binding file of #20 may require enlargement to #40 or #50. Canal shaping is performed using a crown-down technique with rotary nickel-titanium (NiTi) instruments.
Throughout the shaping process, continuous irrigation with sodium hypochlorite to dissolve organic debris and disinfect the canal is performed with total volume of 10ml/canal. After the final shaping, the canal is dried with sterile paper points, leaving it ready for medication placement. For the subjects of GI and GII, nano-ketorolac gel and ketorolac gel respectively (Around 2mm3), placed as medicament inside the root canal while those of GIII a placebo gel is placed. Both will be retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
Randomization and Blinding:
Randomization will be performed using a computer-generated sequence. The patients and outcome assessors will be blinded to the group allocation. Nano-ketorolac production
This study, a formulation containing Ketorolac Tromethamine (KT) at a concentration of 10 mg/mL were developed using Compritol 888 as distinct oleaginous phases. Span 60 was incorporated as a surfactant at a concentration of 1.5%, while the drug-to-oleaginous phase ratio was maintained at 1:2. The Solid Lipid Nanoparticles (SLNs) were formulated using high-shear homogenization to ensure optimal particle size and stability. The nano-Ketorolac will be manufactured in the college of phramaceutical sciences and drug manufacturing, Misr University for Science and Technology, , Egypt.
Statistical Analysis Data will be analyzed using SPSS software. Data will be tested for its normal distribution; accordingly, the appropriate test will be conducted. Statistical significance will be set at p < 0.05.
Ethical Considerations
- The study will be conducted in accordance with the Declaration of Helsinki.
- Ethical approval will be obtained from the Institutional Ethical Committee of Misr University for Science and Technology.
- Informed consent will be obtained from all participants before their inclusion.
- Patients will be informed of their right to withdraw at any time without consequences.
- Data confidentiality will be maintained throughout the study.
Pain management in endodontics has been extensively studied, with a focus on pharmacological interventions, anesthetic techniques, and intracanal medicaments to improve post-operative outcomes. Several studies have explored the effectiveness of NSAIDs, corticosteroids, and advanced anesthetic techniques in controlling pain, but challenges persist, particularly in cases involving necrotic pulp and apical periodontitis.
Detailed description
Study Design: This study will be a randomized, double-blinded, placebo-controlled clinical trial.
Participants and Setting: The study will be conducted at the clinics of Collage of Oral and dental surgery, Misr University for Science and Technology. Patients diagnosed with necrotic pulp and apical periodontitis requiring root canal treatment will be recruited.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
- Model description
- randomized, double-blinded, placebo-controlled clinical trial
| Arm | Type | Receives |
|---|---|---|
| GI | Experimental | Drug: intracanal nano-ketrolacThe nano-ketrolac gel will be introduced intracanal after cleaning and shaping is performed. |
| GII | Experimental | Drug: ketrolac gelketrolac gel will be introduced intracanal after cleaning and shaping is performed. |
| GIII | Placebo comparator | Drug: A placebo gelA placebo gel will be introduced intracanal after cleaning and shaping is performed. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Patients aged 18-50 years.
- Patients who are diagnosed with necrotic pulp and chronic apical periodontitis in a single-rooted tooth.
- Patients who provide written informed consent.
- Patients with no systemic diseases affecting pain perception or wound healing.
Key exclusion criteria (4 listed)
- Patients with irreversible pulpitis or acute periapical abscess
- Patients with a history of NSAID or opioid use within 24 hours before treatment.
- Pregnant or lactating women.
- Patients who require more than two-visits root canal treatment due to anatomical or pathological factors.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intracanal nano-ketrolacFor the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit. | Drug | GI |
| ketrolac gelFor the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit. | Drug | GII |
| A placebo gela placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit. | Drug | GIII |
Primary outcome
post-endodontic pain
Time frame: • Pre-treatment (baseline) • 6 hours post-treatment • 12 hours post-treatment • 24 hours post-treatment • 48 hours post-treatment • 7 days post-treatment
Pain intensity will be assessed using the Visual Analog Scale (VAS) on a 10-point scale (0 = no pain, 10 = worst pain imaginable
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 39780175Kumar G, Jena S, Manila N, Fareed M, Karobari MI. Incidence of postoperative pain after single-visit and multiple-visit root canal therapy: a systematic review. BMC Oral Health. 2025 Jan 8;25(1):47. doi: 10.1186/s12903-024-05412-1.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eman Maged Fouad, PHD principal investigator
Lecturer of Endodontics, Collage of Oral and Dental Surgery, Misr University for Science and Technology, Giza, Egypt.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing intracanal nano-ketrolac and ketrolac gel in people with To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal Treatment, run by Al-Azhar University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
post-endodontic pain (time frame: • Pre-treatment (baseline) • 6 hours post-treatment • 12 hours post-treatment • 24 hours post-treatment • 48 hours post-treatment • 7 days post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07064083, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.